Physicians' Academy for Cardiovascular Education
Prof. Ference shows that PCSK9 inhibition has biologically and therapeutically equivalent effects on the risk of CVD as observed with statins.
ELISA-based measurement of apolipoprotein C-III on individual lipoproteins did not provide additional predictive information on development of coronary artery disease.
Continuous direct factor Xa inhibitor therapy with apixaban was a safe and effective anticoagulation alternative in patients at risk of stroke undergoing atrial fibrillation catheter ablation.
The new guidelines on management of CVD during pregnancy consider new evidence on diagnostic techniques, risk assessment and drug therapy that became available since the 2012 edition.
ESC 2018 The benefit of sacubitril/valsartan in HFrEF is not subject to debate, but opinions do vary on when to use it. An impression of the arguments on whether or not it should be the starting treatment.
Prof. Van der Meer describes the prevalence of hyperkalemia and its effects on the use of RAAS inhibition and discusses some potential novel potassium binders.
In obese individuals without diabetes, semaglutide significantly and dose-dependently reduced body weight compared with placebo and liraglutide, on top of healthy diet and exercise.
A subanalysis of the CANTOS study showed that modulation of the IL-6 signaling pathway with IL-1β inhibitor canakinumab, associates with reduced CV event rates, independent of lipid lowering.
The prospective Copenhagen Male study followed men for 46 years and showed that cardiorespiratory fitness is dose-dependently associated with longevity in middle-aged men without CVD.
ESC 2018 In this debate, the different viewpoints supporting the European and American Guidelines on Hypertension were fiercely defended, although overlap prevails.
ESC 2018 In a randomized trial treatment with tafamidis resulted in impressive, significant reduced mortality and hospitality due to CV events in patients with ATTR-CM and HF.
ESC 2018 Dr Allard-Ratick shares the surprising result that HDL-C levels >60 mg/dl (1.5 mmol/L) were associated with a nearly two-fold increase in the risk of CV death or MI in adults with CV disease.
